Alpha 2.0
Login Register
» Articles » PMID: 25287182

Efficacy and Tolerability of Blonanserin in 48 Patients with Intractable Schizophrenia

Overview
Journal Acta Neuropsychiatr
Publisher Cambridge University Press
Date 2014 Oct 8
PMID 25287182
Citations 3
Authors
Manabu Takaki
Yuko Okahisa
Masafumi Kodama
Yutaka Mizuki
Shinji Sakamoto
Hiroshi Ujike
Yosuke Uchitomi
Affiliations
Soon will be listed here.
Citing Articles

Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia.

Xu B, Jin K, Wu H, Liu X, Wang X, Sang H World J Psychiatry. 2024; 14(11):1735-1745.

PMID: 39564169 PMC: 11572666. DOI: 10.5498/wjp.v14.i11.1735.

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study.

Woo Y, Yoon B, Jeon B, Seo J, Nam B, Lee S Clin Psychopharmacol Neurosci. 2019; 17(3):423-431.

PMID: 31352709 PMC: 6705098. DOI: 10.9758/cpn.2019.17.3.423.

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study.

Woo Y, Park J, Kim D, Sohn I, Hwang T, Park Y Psychiatry Investig. 2016; 13(4):458-67.

PMID: 27482249 PMC: 4965658. DOI: 10.4306/pi.2016.13.4.458.